

INDEX

1.0 INTRODUCTION.....	1
2.0 LITERATURE REVIEW	11
2.1 MATRIX SYSTEMS.....	16
2.1.1 MECHANISM OF DRUG RELEASE FROM HYDROPHILIC MATRICES	23
2.2 OSMOTIC SYSTEMS	26
2.2.1 PRINCIPAL OF OSMOSIS.....	26
2.2.2 TYPES OF OSMOTIC PUMP SYSTEM.....	29
2.2.2.1 ASYMMETRIC MEMBRANES.....	29
2.2.2.2 ELEMENTARY OSMOTIC PUMP (EOP)	35
2.2.2.3 PUSH-PULL OSMOTIC PUMP (PPOP)	40
2.2.2.4 CONTROLLED POROSITY OSMOTIC PUMPS (CPOP)	41
3.0 ANALYTICAL METHODS (BUTORPHANOL TARTRATE).....	59
3.1. PREPARATION OF REAGENTS AND BUFF.....	60
3.2. ESTIMATION OF BUTORPHANOL TARTRATE.....	60
3.3 ESTIMATION OF BT IN FORMULATION FOR ASSAY.....	70
3.4 ESTIMATION OF BT IN FORMULATION FOR CONTENT UNIFORMITY	70
3.5 ESTIMATION OF BT FOR IN-VITRO RELEASE	70
3.6 SEM ANALYSIS	74
3.7 DISCUSSION	74
4.0 FORMULATION DEVELOPMENT BUTORPHANOL TARTRATE.....	78
4.1 DRUG SUBSTANCE:.....	79
4.2 PHARMACOKINETICS.....	80
4.3 PHARMACODYNAMIC PROPERTIES	81
4.4 EXCIPIENTS:.....	82
4.4.1 EXCIPIENT USED IN DRUG PRODUCT:	82

INDEX

4.4.2 SUPPLIERS SPECIFICATIONS OF THE EXCIPIENTS	83
4.4.3 DRUG EXCIPIENTS COMPATIBILITY STUDY:.....	90
4.5 DRUG PRODUCT FORMULATION DEVELOPMENT:	94
4.5.1 PREDICTED PLASMA CONCENTRATION OF BUTORPHANOL TARTRATE .	95
4.5.2 QUALITY TARGET PRODUCT PROFILE (QTTP) :	96
4.5.3 SELECTION OF MANUFACTURING PROCESS:	97
4.5.4 PROCESS FLOW CHART	98
4.5.5 UNIT OPERATIONS OF THE PREPARATION PROCESS	98
4.5.6 OPTIMISATION OF OSMOGEN COMPOSITION IN THE CORE	99
4.5.7 OPTIMISATION OF COATING	101
4.5.7.1 OPTIMISATION OF LEVEL OF PORE FORMER IN THE COATING	
MEMBRANES.	103
4.5.7.2 OPTIMISATION OF COATING THICKNESS (WEIGHT GAIN).....	104
4.5.7.3 OPTIMISED COATING FORMULA.....	105
4.6 RESULTS	108
4.6.1 PRE-COMPRESSION CHARACTERIZATION	108
4.6.2 CHARACTERIZATION OF CORE TABLETS.....	108
4.6.3 CHARACTERIZATION OF COATED CPOP	109
4.6.3.1 THICKNESS OF EXHAUSTED COATING MEMBRANE THROUGH SEM	
ANALYSIS.....	110
4.6.3.2 EFFECT OF PH ON DRUG RELEASE	110
4.6.3.3 EFFECT OF AGITATION INTENSITY	112
4.6.3.4 DOSE DUMPING STUDY	115
4.6.3.6 OBSERVATION OF BEFORE AND AFTER DISSOLUTION	118
4.7 RESULT OF DEVELOPMENT STUDIES	119

INDEX

4.7.1 COMPONENTS OF THE DRUG PRODUCT.....	119
4.7.2 OPTIMISED COATING SOLUTION COMPOSITION	120
4.7.3 CRITICAL QUALITY ATTRIBUTES: (CQAS)	121
4.7.4 CRITICAL PROCESS PARAMETERS (CPPS)	121
4.8 CONCLUSION.....	122
5. ANALYTICAL METHODS (LORNOXICAM).....	124
5.1 PREPARATION OF REAGENTS AND BUFFERS	125
5.1.1 PREPARATION OF ACETATE BUFFER PH 4.5	125
5.1.2 PREPARATION OF PHOSPHATE BUFFER PH 7.5	126
5.2 ESTIMATION OF LORNOXICAM.....	126
5.2.1 ESTIMATION OF LORNOXICAM IN ACETATE BUFFER 4.5, PHOSPHATE BUFFER 7.5 AND PBS 7.5 : METHANOL (50: 50)	126
5.2.1.1 PREPARATION OF STANDARD STOCK SOLUTIONS OF LORNOXICAM IN PBS PH 7.5	126
5.2.1.2 CALIBRATION CURVE OF LORNOXICAM IN PBS PH 7.5	126
5.2.1.3 PREPARATION OF STANDARD STOCK SOLUTIONS OF LORNOXICAM IN ACETATE BUFFER PH 4.5	128
5.2.1.4 CALIBRATION CURVE OF LORNOXICAM IN ACETATE BUFFER PH 4.5	128
5.2.1.5 PREPARATION OF STANDARD STOCK SOLUTIONS OF LORNOXICAM IN PBS 7.5 : METHANOL (50 : 50).....	130
5.2.1.6 CALIBRATION CURVE OF LORNOXICAM IN PBS 7.5 : METHANOL.....	131
5.3 ESTIMATION OF LORNOXICAM IN FORMULATION FOR ASSAY	133
5.4 ESTIMATION OF LORNOXICAM IN FORMULATION FOR CONTENT UNIFORMITY	133
5.5 ESTIMATION OF LOR FOR IN-VITRO RELEASE.....	133

INDEX

5.6 HPLC METHOD FOR ESTIMATION OF LORNOXICAM.....	134
5.7 DISCUSSION	137
5.8 REFERENCES	139
6.0 FORMULATION DEVELOPMENT LORNOXICAM (LXM).....	140
6.1 DRUG SUBSTANCES.....	141
6.2 PHARMACOKINETICS.....	141
6.3 PHARMACODYNAMIC PROPERTIES	143
6.4 EXCIPIENTS.....	144
6.4.1 EXCIPIENT USED IN DRUG PRODUCT	144
6.4.2 SUPPLIER SPECIFICATIONS OF THE EXCIPIENTS	145
6.4.3 DRUG EXCIPIENTS COMPATIBILITY STUDY	148
6.5 DRUG PRODUCT FORMULATION DEVELOPMENT	152
6.5.1 PREDICTED PLASMA CONCENTRATION OF LORNOXICAM	152
6.5.2 QUALITY OF TARGET PRODUCT PROFILE (QTTP)	155
6.5.3 SELECTION OF MANUFACTURING PROCESS	155
6.5.3.1 INITIAL DEVELOPMENT COMPOSITION	156
6.5.3.2 OPTIMISATION OF CORE FOR ACHIEVING INITIAL RELEASE	158
6.5.3.3 OPTIMISATION OF EXTENDED RELEASE PART	160
6.5.4 PROCESS FLOW CHART OF THE OPTIMISED PROCESS.....	162
6.5.5 UNIT OPERATIONS OF THE PREPARATION PROCESS	162
6.6 RESULT	166
6.6.1 PRE-COMPRESSION CHARACTERISATION.....	166
6.6.2 COMPRESSED FORMULATION	167
6.6.3 EFFECT OF AGITATION INTENSITY	168
6.6.4 EFFECT OF DISSOLUTION VOLUME	170

INDEX

6.6.5 DOSE DUMPING STUDY	171
6.7 RESULT OF DEVELOPMENT STUDIES	173
6.7.1 COMPONENTS OF THE DEVELOPED DRUG PRODUCT	173
6.7.2 COATING PROCESS	174
6.7.3 CRITICAL QUALITY ATTRIBUTES: (CQAS)	174
6.7.4 CRITICAL PROCESS PARAMETERS (CPPS)	175
6.8 CONCLUSION.....	175
6.9 REFERENCES	176
7.0 STABILITY STUDIES	178
7.1 MATERIALS AND METHODS	178
7.2 PACK STYLE	178
7.3 EVALUATION OF THE SAMPLES	179
7.4 IN-HOUSE SPECIFICATIONS AND LIMITS	179
7.5 RESULTS	180
7.6 DISCUSSION	188
7.7 CONCLUSION	188
7.8 REFERENCES	188
8.0 IN-VIVO PHARMACOKINETIC STUDIES	190
8.1 METHODS	190
8.1.1 ANIMALS	190
8.1.2 DOSING PROCEDURE	190
8.1.3 BLOOD SAMPLING PROCEDURE	190
8.1.4 SAMPLING PROCEDURE	191
8.2 STUDY DESIGN	192
8.3 STATISTICAL ANALYSIS	193

INDEX

8.4 PREPARATION OF EQUIVALENT FORMULATION FOR RAT MODEL	193
8.5 PHARMACOKINETIC STUDIES OF BUTORPHANOL TARTRATE FORMULATION	194
8.6 LORNOXICAM	199
8.7 METHODS	199
8.7.1 ANIMALS	199
8.7.2 DOSING PROCEDURE	199
8.7.3 BLOOD SAMPLING PROCEDURE	199
8.7.4 SAMPLING PROCEDURE:	200
8.8 STUDY DESIGN	201
8.9 STATISTICAL ANALYSIS	202
8.10 PREPARATION OF EQUIVALENT FORMULATION FOR RAT MODEL	202
8.11 PHARMACOKINETIC STUDIES OF LORNOXICAM FORMULATION	204
8.12 CONCLUSIONS	208
8.13 REFERENCES	209
9.0 SUMMARY & CONCLUSION	211